207 related articles for article (PubMed ID: 20427935)
1. Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients.
AlGahtani FH; Alshaikh M; AlDiab A
Ann Saudi Med; 2010; 30(3):198-202. PubMed ID: 20427935
[TBL] [Abstract][Full Text] [Related]
2. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Simpson E; Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
Cochrane Database Syst Rev; 2012 Mar; (3):CD005011. PubMed ID: 22419303
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated coagulation factor VII and bleeding trauma patients.
Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
[TBL] [Abstract][Full Text] [Related]
5. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
[TBL] [Abstract][Full Text] [Related]
6. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
[TBL] [Abstract][Full Text] [Related]
7. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly.
Duchesne JC; Mathew KA; Marr AB; Pinsky MR; Barbeau JM; McSwain NE
Am Surg; 2008 Dec; 74(12):1159-65. PubMed ID: 19097529
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
Palmason R; Vidarsson B; Sigvaldason K; Ingimarsson JP; Gudbjartsson T; Sigurdsson GH; Onundarson PT
Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
[TBL] [Abstract][Full Text] [Related]
9. Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.
Bhat S; Yadav SP; Anjan M; Dinand V; Sachdeva A
Indian J Pediatr; 2011 Aug; 78(8):961-8. PubMed ID: 21328080
[TBL] [Abstract][Full Text] [Related]
10. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.
Gandhi MJ; Pierce RA; Zhang L; Moon MR; Despotis GJ; Moazami N
J Cardiothorac Surg; 2007 Jul; 2():32. PubMed ID: 17617902
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center.
Sartori MT; Imbergamo S; Zanon E; Bonaccorso G; Pittoni G; Feltracco P; Ori C; Pagnan A; Cella G
Clin Appl Thromb Hemost; 2009 Dec; 15(6):628-35. PubMed ID: 19605376
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients.
Felfernig M;
J R Army Med Corps; 2007 Mar; 153(1):32-9. PubMed ID: 17575875
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.
Omar HR; Enten G; Karlnoski R; Ching YH; Mangar D; Camporesi EM
Drugs R D; 2015 Jun; 15(2):187-94. PubMed ID: 25862216
[TBL] [Abstract][Full Text] [Related]
14. [Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].
Bardon J; Fink J; de Montblanc J; Bergmann JF; Sarrut B; Benhamou D
Ann Fr Anesth Reanim; 2013 Oct; 32(10):659-64. PubMed ID: 23953834
[TBL] [Abstract][Full Text] [Related]
15. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.
Boffard KD; Choong PI; Kluger Y; Riou B; Rizoli SB; Rossaint R; Warren B;
Transfusion; 2009 Dec; 49 Suppl 5():240S-7S. PubMed ID: 19954486
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
17. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
Pham HP; Hsu SX; Parker-Jones S; Samstein B; Diuguid D; Schwartz J
Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
20. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.
Rizoli SB; Boffard KD; Riou B; Warren B; Iau P; Kluger Y; Rossaint R; Tillinger M;
Crit Care; 2006; 10(6):R178. PubMed ID: 17184516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
